Clinical trials: Vascular And Immunologic Diseases
Renal Impairment, Multiple Myeloma
PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function
This was a multicenter study of the pharmacokinetics (PK) of melphalan during treatment with melflufen and dexamethasone in patients with relapsed refractory multiple myeloma (RRMM) and impaired renal function.
- Trial name
- BRIDGE (NCT03639610)
- Testing
- Melflufen, Dexamethasone
- Where
- 10 sites in Czechia, Greece and 1 more
- Volunteers
- 35 people
- Sponsor
- Oncopeptides AB
Adrenal Insufficiency, Polymyalgia Rheumatica (PMR)
Hydrocortisone and Placebo in Patients With Symptoms of Adrenal Insufficiency After Cessation of Glucocorticoid Treatment
Cortisol, a glucocorticoid (GC) hormone secreted from the adrenal glands, is essential for survival. Cortisol also possesses anti-inflammatory actions and GC formulations (prednisolone) are used to treat many inflammatory…
- Conditions
- Adrenal Insufficiency, Polymyalgia Rheumatica (PMR), Giant Cell Arteritis (GCA)
- Trial name
- REPLACE (NCT05193396)
- Testing
- Hydrocortisone
- Where
- 3 sites in Denmark
- Volunteers
- 100 people
- Sponsor
- Marianne Andersen
Stroke, Guillain-Barre Syndrome
Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology
This study examines the use of an AI-powered virtual assistant for quickly identifying and handling neurological emergencies, particularly in places with limited medical resources.
- Conditions
- Stroke, Guillain-Barre Syndrome, Facial Palsy, Migraine
- Trial name
- AIDEN (NCT06334796)
- Testing
- Virtual Assistant
- Where
- Argentina
- Volunteers
- 10 people
- Sponsor
- Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia
Relapsed or Refractory Multiple Myeloma
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory…
- Trial name
- SUCCESSOR-1 (NCT05519085)
- Testing
- mezigdomide, Pomalidomide, Bortezomib
- Where
- 266 sites in United States, Argentina and 27 more
- Volunteers
- 810 people
- Sponsor
- Celgene
Chronic Spontaneous Urticaria
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of chronic spontaneous urticaria (CSU) that is not effectively treated by antihistamines which are…
- Trial name
- NCT07219615
- Testing
- Ritlecitinib 50 mg, Ritlecitinib 100 mg
- Where
- 77 sites in United States, Bulgaria and 8 more
- Volunteers
- 200 people
- Sponsor
- Pfizer
Adult Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma Recurrent
A Phase II Study of Doxycycline in Relapsed NHL
The purpose of this study is to determine whether doxycycline is effective in the treatment of relapsed Non Hodgkin Lymphomas (NHL).
- Conditions
- Adult Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma Recurrent, Lymphoma, Follicular, Marginal Zone B-Cell Lymphoma
- Trial name
- NCT02086591
- Testing
- Doxycycline
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Rochester
Raynaud Phenomenon Due to Trauma, Raynaud Disease
Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud
Objective: To compare the efficacy of topical 10% nifedipine versus 5% sildenafil in patients with secondary Raynaud's phenomenon (RP).
- Conditions
- Raynaud Phenomenon Due to Trauma, Raynaud Disease, System; Sclerosis, Lupus Erythematosus, Systemic
- Trial name
- NCT03027674
- Testing
- 10% nifedipine cream, 5% sildenafil cream
- Where
- Chile
- Volunteers
- 10 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Hematologic Malignancies, Solid Tumor
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Multicenter, open-label, phase 1a/1b trial of PF-07901800 (TTI-621) in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
- Trial name
- NCT02663518
- Testing
- PF-0791800 (TTI-621), PF-07901800 (TTI-621) plus Rituximab, PF-07901800 (TTI-621) plus Nivolumab
- Where
- 51 sites in United States, Canada
- Volunteers
- 249 people
- Sponsor
- Pfizer
Subdural Hematoma, Chronic
Endovascular vs Conservative Treatment in Patients With Chronic Subdural Hematomas and Mild Symptoms
Embotrial-1 is an Italian multicenter prospective randomized clinical trial with open-label treatment and blinded outcome assessment (PROBE) to assess the superiority of MMA embolization compared to conservative treatment.
- Trial name
- NCT06274580
- Testing
- embolization of the middle meningeal artery
- Volunteers
- 300 people
- Sponsor
- Ospedale Policlinico San Martino
Lymphoma, Advanced Prostate Cancer
Whole Body MRI in Oncology
Multicenter, observational, prospective, study. All patients will be treated and monitored according to the local clinical practice.
- Conditions
- Lymphoma, Advanced Prostate Cancer, Advanced Breast Cancer, Monoclonal Gammopathy of Undetermined Significance
- Trial name
- ONCO-MRI (NCT06895291)
- Testing
- Whole Body-Magnetic Resonance Imaging (WB-MRI)
- Where
- 3 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Waldenstrom's Macroglobulinemia
Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia
Pomalidomide is a newly discovered drug that may stop cancer cells from growing abnormally. Pomalidomide may also stimulate the immune system to fight the cancer cells and possibly improve the effectiveness of dexamethasone and…
- Trial name
- NCT01078974
- Testing
- pomalidomide, dexamethasone, rituximab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Steven P. Treon, MD, PhD
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Adult Acute Lymphoblastic Leukemia
Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant
This phase I/II trial studies the side effects of donor lymphocyte infusion and to see how well it works in treating patients with persistent, relapsed (disease that has returned), or progressing cancer after donor hematopoietic…
- Conditions
- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Hodgkin Lymphoma
- Trial name
- NCT00068718
- Testing
- Therapeutic Allogeneic Lymphocytes
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 35 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, Lymphoma
Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant
RATIONALE: Giving an infusion of donor lymphocytes may be able to kill cancer cells in patients with hematologic cancer that has come back after a donor stem cell transplant.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00534118
- Testing
- donor lymphocytes
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Roswell Park Cancer Institute
Leukemia, Lymphoma
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00176475
- Testing
- rituximab, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Multiple Myeloma
Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma
The purpose of the study is to determine the safety of MLN9708 as maintenance therapy following allogeneic stem cell transplant in patients with multiple myeloma.
- Trial name
- NCT02168101
- Testing
- MLN9708
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- SCRI Development Innovations, LLC
Multiple Myeloma, Neoplasms
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible
This is a phase 1/2, open label, study designed to assess the safety and clinical activity of different belantamab mafodotin doses in combination with daratumumab, lenalidomide and dexamethasone.
- Conditions
- Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell, Gammopathy, Monoclonal
- Trial name
- NCT05280275
- Testing
- Belantamab Mafodotin-Blmf, Daratumumab, Lenalidomide
- Where
- 2 sites in Greece
- Volunteers
- 36 people
- Sponsor
- Hellenic Society of Hematology
Multiple Myeloma
Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma
This study is to determine whether addition of Revlimid to standard therapy will increase overall and complete response rates compared to historical standard frontline therapy and whether this combination treatment has fewer side…
- Trial name
- NCT00843310
- Testing
- Lenalidomide (Revlimid), Melphalan, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- NYU Langone Health
TBI (Traumatic Brain Injury), Status Epilepticus
Augmented Renal Clearance in Neurocritical Care
Stroke, severe brain injury, uncontrolled seizures and brain infections are the most common life-threatening neurological illnesses in the world with an estimated combined annual hospital management cost of up to 44 billion…
- Conditions
- TBI (Traumatic Brain Injury), Status Epilepticus, Bacterial Meningitis, Augmented Renal Clearance (ARC)
- Trial name
- Neuro-ARC (NCT07410624)
- Where
- 3 sites in United States, Canada
- Volunteers
- 512 people
- Sponsor
- University of Alberta
Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma
A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
This study will include participants with relapsed/refractory (R/R) Multiple Myeloma (MM). MM is a type of cancer of the blood. This study will also include participants with relapsed/refractory (R/R) Diffuse Large B-Cell…
- Conditions
- Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma, Diffuse Large B Cell Lymphoma Refractory, Multiple Myeloma in Relapse
- Trial name
- NCT05121103
- Testing
- EZM0414
- Where
- 8 sites in United States
- Volunteers
- 13 people
- Sponsor
- Epizyme, Inc.
Multiple Myeloma
Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma
This is a Single-center, Open-label, Single-arm Exploratory Clinical Study to evaluate the safety and efficacy of Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy in relapsed or refractory multiple myeloma…
- Trial name
- NCT05549973
- Testing
- Anlotinib Hydrochloride Capsule
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.